Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arvinas, Inc. (NASDAQ: ARVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on targeted protein degradation. Arvinas files current reports on Form 8-K, along with periodic reports such as Forms 10-K and 10-Q, to describe material events, financial results and key developments across its PROTAC pipeline.
In its 8-K filings, Arvinas reports items such as quarterly financial results and corporate updates, presentation of clinical and preclinical data for programs including ARV-102 (a PROTAC LRRK2 degrader), ARV-393 (a BCL6 degrader for non-Hodgkin lymphoma) and ARV-806 (a KRAS G12D degrader for solid tumors), and regulatory milestones for vepdegestrant, its investigational PROTAC estrogen receptor degrader for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. The company also uses 8-Ks to disclose collaboration updates with Pfizer, workforce and cost management actions, and Board and executive changes.
Through this page, users can review how Arvinas describes its PROTAC platform, clinical-stage programs and corporate actions in official SEC documents. Real-time updates from EDGAR allow investors to see new 8-Ks and other filings as they are posted, while AI-powered tools on Stock Titan can help summarize lengthy filings, highlight key sections on topics such as clinical data, regulatory status and capital allocation, and surface patterns across multiple ARVN disclosures.
For those researching ARVN, these filings are a primary source for understanding the status of vepdegestrant’s New Drug Application, the design and progress of trials in oncology and neurodegeneration, and the financial and governance information Arvinas reports to regulators and shareholders.
The Vanguard Group filed Amendment No. 5 on a Schedule 13G/A reporting beneficial ownership of 0 shares of Arvinas Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026
The filing cites SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately following the realignment. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Arvinas, Inc. Chief Medical Officer Noah Berkowitz reported an automatic share disposition related to tax withholding. On March 18, he sold 6,435 shares of common stock at an average price of $11.1004 per share. According to the footnote, this sale was made automatically by the company to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on March 18, 2024, and did not represent a discretionary trade. After this transaction, he directly held 202,503 shares of Arvinas common stock.
Arvinas, Inc. reported positive Phase 1 data for ARV-102, an investigational oral PROTAC degrader of LRRK2 in patients with Parkinson’s disease. Multiple daily doses of 20 mg, 40 mg, and 80 mg for 28 days were well tolerated, with only mild adverse events, no serious adverse events, no discontinuations, and no deaths, and no significant changes in lung function.
ARV-102 showed brain penetration with cerebrospinal fluid exposure increasing in a dose-dependent manner and a mean plasma half-life of 68 hours. It achieved approximately 50% or greater LRRK2 reduction in cerebrospinal fluid at all doses by day 14, maintained through day 28, and reduced endolysosomal and neuroinflammatory biomarkers such as CD68 and GPNMB.
Based on these results, Arvinas plans to continue developing ARV-102 in neurodegenerative diseases linked to LRRK2 and endolysosomal dysfunction and, pending regulatory feedback, intends to start a Phase 1b trial in progressive supranuclear palsy in the second quarter of 2026, with potential initiation of a registrational trial in late 2026.
Arvinas, Inc. submitted a Rule 144 notice reporting the settlement of 6,022 vested restricted stock units on 03/18/2026 through Morgan Stanley Smith Barney LLC and a prior sale of 5,685 shares by Noah Berkowitz on 02/13/2026 for $67,594.65.
The filing lists the securities as Common stock to be sold via settlement of vested RSUs; the sale by Berkowitz is reported in the "Securities Sold During The Past 3 Months" section.
Teel Randy reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. President and CEO Randy Teel reported an amended equity award, correcting the size of a previously disclosed grant of restricted stock units (RSUs) made on February 26, 2026.
The corrected grant covers 147,179 RSUs, each representing one share of common stock for no cash payment, under the company’s 2018 Stock Incentive Plan. The RSUs vest in four equal annual installments on February 12 of 2027, 2028, 2029 and 2030, contingent on his continued service. Following this correction, Teel is shown as beneficially owning 296,875 shares after the reported transaction.
The amendment fixes an earlier clerical error that had misstated the award as 147,791 RSUs and adjusts the reported post-transaction holdings to match the accurate grant amount.
Arvinas, Inc. director Briggs Morrison reported an open-market purchase of 20,000 shares of the company’s common stock. The transaction took place on March 6, 2026 at a weighted average price of $13.4035 per share, and increased his direct holdings to 96,021 shares. A footnote explains that the purchase price is a weighted average of multiple trades executed between $13.364 and $13.45 per share.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, reported equity awards granted on February 26, 2026. He acquired a stock option for 18,504 shares and a grant of 12,420 shares of common stock, both at an exercise/issuance price of $0.00 per share.
The 12,420 restricted stock units each represent one future share of common stock and will vest in four equal annual installments on February 26, 2027, 2028, 2029, and 2030, subject to his continued service. The 18,504 option shares vest over four years: one quarter on February 26, 2027, with the remaining shares vesting in equal monthly installments through February 26, 2030, also contingent on continued service.
Cacace Angela M reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. reported that Chief Scientific Officer Angela M. Cacace received new equity awards on February 26, 2026. She was granted options to purchase 67,000 shares of common stock and 45,000 restricted stock units, each RSU representing one share upon settlement for no cash payment.
The RSUs vest in four equal annual installments on February 26 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options also vest over four years, with 25% vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments through February 26, 2030, subject to ongoing employment.
ARVINAS, INC. reported that Chief Medical Officer Noah Berkowitz received new equity awards. He was granted stock options for 67,000 shares at an exercise price of $0.0000 per share and 45,000 restricted stock units, each representing one share of common stock upon settlement for no consideration.
The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued service. The option also vests over four years, with one-quarter vesting on February 26, 2027 and the remainder in equal monthly installments through February 26, 2030. Following these grants, Berkowitz directly owns 208,938 shares of common stock.
Saik Andrew reported acquisition or exercise transactions in this Form 4 filing.
Arvinas, Inc. reported that its Chief Financial Officer, Andrew Saik, received equity awards on February 26, 2026. He was granted options to purchase 67,000 shares and 45,000 restricted stock units, both at no cash cost, vesting gradually over four years, contingent on continued service.